Objective: Early goal-directed therapy (EGDT) reduced mortality from septic shock in a single-center trial. However, implementation of EGDT faces several barriers, including perceived costs and logistic difficulties. We conducted a decision analysis to explore the potential costs and consequences of EGDT implementation.
S evere sepsis and septic shock are associated with high mortality and cost, affecting approximately 750,000 Americans annually (1) . Consequences can be especially severe when occurring outside the intensive care unit (ICU), because onset is often cryptic and care delayed (2) . In 2001, Dr. Rivers and colleagues (3) reported early goal-directed therapy (EGDT) for severe sepsis and septic shock reduced mortality when applied in the emergency department (ED) before ICU admission. EGDT involves identification of high-risk patients, invasive monitoring, and 6 hrs of protocolized resuscitation with fluids, vasoactive agents, and packed red blood cells. Although these strategies are common in the ICU (4), they are not in the ED.
EGDT is conceptually similar to established protocols for early management of trauma (5) , myocardial infarction (6) , and stroke (7) . Although now widely accepted, these protocols, and EGDT, encountered barriers when first disseminated, including ED overcrowding (8) ; inadequate staffing and equipment; lack of education, training, and procedural competency (9); negative perceptions; and clinician and organizational resistance to change (10) . Many of these barriers relate to costs, resource use, and value, and may be affecting adoption of EGDT. Concern also exists over EGDT's generalizability and efficacy (11) and detailed cost data from the original trial previously have not been analyzed. Our goal was to use the theoretical strengths of formal decision analysis to explore the potential costs and consequences of EGDT implementation for hospitals and for society, under alternative implementation strategies.
MATERIALS AND METHODS
Our primary objective was to examine the clinical and economic consequences of EGDT implementation from the hospital perspective (or "hospital case"). We also generated a longterm, societal perspective "reference case," following the recommendations of the U.S. Public Health Service Panel on Cost-Effectiveness in Health and Medicine (12) and the American Thoracic Society Panel on Understanding Costs and Cost-Effectiveness in Critical Care (13) . The University of Pittsburgh Institutional Review Board approved the study.
Modeling EGDT Implementation. We designed a decision model comparing EGDT to usual care under three implementation strategies ( Fig. 1) : an ED-based strategy, where ED staff provide both screening and EGDT; a "mobile team" strategy, where ED staff screen for candidates and alert ICU staff, who come to the ED to provide EGDT; and an ICU-based strategy, where ED staff screen and identify candidates but transfer them to the ICU where ICU staff provide EGDT. We considered challenges implementing EGDT would pose, including patient identification, workforce modification, and equipment acquisition, and populated our model with data from the original trial and published literature ( Table 1) . We estimated annual ED severe sepsis and septic shock volume from published sources (Appendix 1) and ED nurse-to-patient ratios from a seven-ED convenience sample (Appendix 2).
We quantified incremental costs per incremental effects for the hospital case as hospital costs per hospital survivor, and for the refer-ence case as costs per quality-adjusted life-yr (QALY).
Defining Usual Care. The original trial's control arm included central venous and arterial pressure monitoring in the ED; however, usual care in most EDs does not. We, therefore, subtracted these monitoring costs from the control arm while patients remained in the ED. We assumed usual ICU care included a standard nonoximetric central line and, if mechanical ventilation was required, an arterial line. This approach biases against EGDT's cost-effectiveness, by decreasing usual care costs in our model.
Effects. We measured incremental effect as the in-hospital mortality difference of the original trial (hospital case), and as the number of QALYs gained (reference case), discounted at a 3% annual rate as per guidelines of the Public Health Service Panel on Cost-Effectiveness in Health and Medicine.
For the reference case, we used the incremental mortality difference from the longest follow-up point in the study (60 days), and as per previous work, modeled long-term survival and QALYs (14) . Briefly, we calculated life-yrs by generating an age-matched life expectancy for each 60-day survivor using U.S. Census life tables, adjusted by the relative risk of death for sepsis survivors (0.51) reported by Dr. Quartin and colleagues (15) . To generate QALYs, we assigned each 60-day survivor the average quality-adjusted survival of someone in the general population (16) with the same life expectancy, rather than the same age. Our approach assigns both lower life expectancy and quality of life to sepsis survivors than those of an age-matched general population, regardless of treatment arm, and closely approximates prospective, long-term follow-up survival data of other sepsis cohorts (17) .
Costs and Resource Use. For the hospital case, we measured incremental costs as the difference in hospital costs between the EGDT and usual care arms, based on the original trial's published resource use data, and supplemented by additional trial data on length of stay (LOS) and use of pulmonary artery catheters and packed red blood cells. These data were obtained from the Henry Ford Health Systems corporate data stores and weighted by the Medicare Cost Report hospital and department-specific cost-to-charge ratios ( Table 2) . We assigned the EGDT arm estimated costs for implementation, including start-up (equipment acquisition, training) and delivery (additional personnel time, screening) costs (Table  1 ; Fig. 2 ). For the reference case, we estimated posthospital lifetime healthcare costs using age-specific healthcare costs from the 1987 National Medical Expenditure Survey projected to the year 2000. As with quality of life, we assigned age-specific costs based on predicted remaining years of life rather than actual age. As average costs rise with age, this approach assigns higher costs to sepsis survivors than those incurred by an age-matched general population. As per previous work, we added nursing home cost estimates, and as with long-term effects, applied a 3% annual discount rate (14) . Costs were updated to year 2005 U.S. dollars using the Consumer Price Index.
Sensitivity Analyses. We conducted oneway sensitivity analyses for both cases and across all strategies, varying our assumptions for clinical effects, healthcare costs, and hospital-level variables ( Table 3 ). As per guidelines of the Public Health Service Panel on Cost-Effectiveness in Health and Medicine, point estimates were set based on published trial data. For baseline mortality and EGDT's efficacy in reducing mortality, LOS, and mechanical ventilation, we deemed it unlikely these variables could be greater than that published. We, therefore, ranged these variables from null to that reported in the original trial, an approach which biases against EGDT. From a hospital perspective, deciding to implement EGDT requires an immediate new outlay of money vs. future theoretical gains in efficacy and cost savings. This decision is further complicated by concerns about whether the published results can be reproduced locally. To explore the tension around this decision, we conducted a 2-way sensitivity analysis from the hospital perspective for the ED-based strategy, comparing total implementation costs to in-hospital mortality reduction, while holding all downstream costs neutral (i.e., ignoring potential cost savings of EGDT).
Statistical Analyses. We used Wilcoxon's rank-sum test to compare continuous data and the chi-square test to compare categorical data. To estimate the distributions around our hospital case and reference case cost-effectiveness estimates, we used Monte Carlo simulation to generate 1,000 cohorts of 263 simulated cases (size of original study population), and reproduced the age characteristics of the study population using bootstrapping with replacement (27, 28) . We described these distributions using 95% confidence ellipses applying Fieller's method on the bootstraps (29) , and the estimated probabilities cost-effectiveness ratios fell below illustrative thresholds. Because of lack of patient-level LOS data, we expressed hospital costs as mean and 95% confidence ellipses, rather than median and interquartile range. We conducted statistical analyses and simulations in Data by TreeAge (Data Professional, TreeAge Software, Williamstown, MA) and SAS (SAS Institute, Cary, NC).
RESULTS
EGDT Implementation Costs. The ED simulated in our model had an annual volume of 29,100 visits, with 91 severe sepsis and septic shock cases. Start-up costs ranged from $12,973 for the ICU-based strategy to $29,952 for the ED-based strat- Table 1 . Implementation strategy assumptions for three strategies-emergency department (ED)-based, mobile team, and intensive care unit (ICU)-based; Calculations are based on an average ED seeing 91 severe sepsis/septic shock patients per year with an annual total ED patient volume of 29,100 For the ICU-based strategy, we assumed for each hr delay in implementing EGDT due to ED-ICU transfer there was a 10% loss in relative efficacy, both for mortality and LOS reduction. The national average ED wait time for an ICU bed is slightly over 4 hrs. d We assumed that wait time will be reduced by the additional training, quality assurance, and personnel time required to implement the ICU-based strategy, and assumed a 2-hr ICU bed wait time. We assumed no delay for the other strategies. Quality assurance (hrs/month) Quality assurance time estimates based on information from centers that have implemented EGDT (21) (22) (23) We assumed that after 72 hrs, the observed difference in transfusion amounts did not change. This biases against EGDT, because although the absolute transfusion amounts would increase after 72 hrs, it is likely that the difference would narrow over time (26) , with the ICU-based strategy yielding the highest cost savings because it had the lowest implementation costs (Fig. 3) .
The 16% absolute increase in hospital survival reported by Dr. Rivers and colleagues for EGDT was assumed for the ED-based and team strategies, but predicted to fall to 12.6% for the ICU-based strategy, due to modeled time delay penalty. LOS savings attributable to EGDT similarly were reduced with the ICUbased strategy. For a hospital treating 91 severe sepsis and septic shock ED patients annually, implementing EGDT would yield average hospital cost savings of $788,606 (95% CI, $206,388 -$1,390,662) and 13 additional hospital survivors. There was 99.5% (ED, 99.4%; team, 99.3%; ICU, 99.8%) probability that EGDT implementation was dominant (cost savings and better outcome) over usual care.
Reference Case. Mean per-patient lifetime costs were $75,196 (95% CI, $62,674 -$88,859) in the usual care arm and $78,370 (95% CI, $67,147-$90,174) in the EGDT arm. Thus, EGDT implementation increased lifetime costs per treated patient by a mean $3,174 (95% CI, Ϫ$10,930 to $17,912) ( Fig. 3) , due to increased survival and subsequent posthospital costs. Incremental costs differed by strategy (ED, $4,141; team, $4,089; ICU, $1,292), with the ICU-based strategy resulting in the lowest cost increase because it had the lowest implementation costs and survival rates. Incremental QALYs gained per treated patient also differed by strategy (ED, 0.59 Ϯ 0.27; team, 0.59 Ϯ 0.27; ICU, 0.47 Ϯ 0.26). The ICUbased strategy had the lowest gain due to the time delay penalty. Overall, EGDT implementation yielded the following ratios (ED, $7,019/QALY; team, $6,931/ QALY; ICU, $2,749/QALY), with high probability that implementation was Ͻ$20,000/QALY (ED, 97.5%; team, 97.7%; ICU, 96.7%) and moderate probability that implementation was dominant (ED, 26.6%; team, 29.7%; ICU, 43.2%).
Sensitivity Analyses. Both cases were robust to our model assumptions and estimates, remaining dominant or Ͻ$20,000/QALY for most variables, including baseline mortality, equipment acquisition costs, and personnel time ( Table 3 ). Cost-effectiveness was most sensitive to implementation delay and EGDT's effect on mortality and survivor ICU LOS. For the hospital case, the "break-even," cost-neutral point where EGDT ceased to be a dominant strategy was at an absolute in-hospital mortality reduction of 7.4% (ICU strategy, 9.2%) and ICU LOS reduction of 2 days (ICU strategy, 2.5 days). The hospital case was also particularly sensitive to time delay for the ICU-based strategy, with the costneutral point being a 5.4-hr delay. The reference case remained Ͻ$20,000/QALY down to a (ED, 5.2%, team, 5.1%; ICU, 1.6%) reduction in 60-day mortality and 9.2-hr delay.
After ignoring all potential cost savings attributable to EGDT and simultaneously varying efficacy and implementation costs, the vast majority of simulations fell below $50,000/additional hospital survivor. However, below 2.5% absolute hospital mortality reduction, EGDT's cost effectiveness rapidly worsens, rising to Ͼ$100,000/ survivor if implementation costs increase ( Fig. 4) . EGDT Ͻ$20,000/QALY over entire range.
EGDT, early goal-directed therapy; N/A, not applicable; QALY, quality-adjusted life-yr; ICU, intensive care unit; LOS, length of stay; MV, mechanical ventilation; ED, emergency department. a EGDT's main effects are reduction in mortality and survivor ICU LOS, presumably due to reduction in organ dysfunction (3) . We, therefore, varied these two parameters together; b Cost per hospital, amortized over 5 yrs. Ranging the amortization period from 2-10 yrs has no significant effect; c $12,973 for the team-and ICU-based strategies, because of lower training requirements; d $12,454 also for the team-based model; $0 for the ICU-based strategy. Substituting the PreSep catheter (Edwards Lifesciences, Irvine, CA) for hourly venous blood gases and a regular central line also had no significant effect, assuming that hourly checks of central venous saturation, as opposed to continuous, had no effect on EGDT's efficacy; e ED sepsis volume ϭ annual ED volume ϫ sepsis incidence. To bias against EGDT, we ranged annual ED volume, because this results in more nurses in our model, and hence higher training costs, as opposed to ranging sepsis incidence, which would not further impact per patient costs in our model; f Cost per hospital; represents the cost of the extra 4 hrs of nurse time and 2 hrs of physician time required to deliver EGDT per treated patient, for 91 patients. Increasing personnel time to 5.5ϫ the point estimate (to simulate hiring 1 nurse full-time equivalent and 1 ⁄2 physician full-time equivalent) had minimal effect on the results.
DISCUSSION
We estimated that implementation of EGDT, using various strategies, is potentially cost-effective and cost-saving. These findings were despite conservative methodology that assigned significant implementation costs to EGDT. Cost savings primarily depended on achieving ICU LOS reductions. If the observed LOS reductions were not achieved, hospital costs rapidly rose, but the societal costeffectiveness ratio appeared likely to be worthwhile under a wide range of assumptions. Our estimates were particularly sensitive to time delay to implementation and EGDT's efficacy in reducing mortality and LOS. Overall, all three implementation strategies yielded relatively similar, favorable cost-effectiveness estimates, suggesting that hospitals can customize EGDT implementation to suit local needs.
Implementation costs are related to preexisting hospital infrastructure. To bias against EGDT, we included not only additional screening, training, and per-sonnel costs, but also the costs of upgrading two ED rooms to be capable of invasive monitoring (Table 1 ). In trauma, stroke, and cardiac centers that already have personnel and infrastructure to manage critical illness, EGDT implementation costs may be less. In three centers that implemented comprehensive sepsis bundles including EGDT, no additional personnel were required (30 -32) . Inhospital medical emergency teams are becoming increasingly widespread, and could similarly be adapted to include EGDT. Standard central lines and serial ScvO2 measurements could be used instead of continuous ScvO2-capable central lines; however, this approach's efficacy is undetermined. Lastly, an ICUbased strategy for EGDT implementation minimizes cost by using existing ICU infrastructure, but potentially suffers from delays in care while awaiting transfer (33) , potentially reducing effectiveness (34, 35) . Reducing ED-ICU transfer time would be essential for an ICU-based strategy.
The hospital case is based on an absolute reduction in hospital costs and effective in-hospital mortality reduction. The usual care arm's hospital cost of $37,823 is comparable to other sepsis cost studies' costs of $32,950 (36) , $37,517 (14) , and $44,600 (37); variation is likely due to differences in cost accounting and case mix. A strength of our study is its basis on the actual patient outcome and resource data of the original trial. However, a key concern of all new interventions is published efficacy vs. generalizable, "realworld" effectiveness; a recent review of highly cited clinical research found it not unusual for subsequent studies to find contradictory or less impressive results (38) . Specific to EGDT, some have expressed concern regarding the study's high baseline mortality, and potential confounding by the research team's presence (11) . We conservatively constructed our decision model to bias against EGDT, and sensitivity analyses showed EGDT would be worthwhile even if mortality reduction and baseline mortality were (29) . Incremental effects are shown on the x-axes and incremental costs are shown on the y-axes. Quadrants to the right of the y-axes represent regions where implementation of EGDT is associated with a net gain in effects. Quadrants above the x-axes represent regions where EGDT is associated with a net increase in costs; conversely, quadrants below the x-axes represent regions where EGDT is associated with a net decrease in costs. The dotted lines are illustrative thresholds. Regions below and to the right of the thresholds are more cost-effective than regions above and to the left of the thresholds. The ellipses are the smallest areas containing, with 95% confidence, the average incremental costs and effects. The three ellipses in each panel represent the three implementation strategies (ED, emergency department-based; team, mobile team-based; ICU, intensive care unit-based). Point estimates are represented by solid dots. In both distributions, the ICU-based strategy results in the lowest efficacy and costs, and is represented by the left-most ellipses. The hospital case distributions lie mainly in the "less costly, more effective" lower right quadrant. The reference case distributions lie mainly in the "more effective, more costly" upper right quadrant, with the majority of simulations falling below the $20,000 per quality-adjusted life-year (QALY) threshold.
considerably less than in the original trial. Several observational studies also have suggested that EGDT is beneficial (30, 39, 40) . Nevertheless, a larger, multicenter randomized trial would provide important confirmation.
In cost-effectiveness studies that incorporate healthcare resource use data, uncertainty also exists if hospitals can realize true LOS savings as opportunity costs (41) . Furthermore, the ED is unlikely to gain credit for such downstream consequences. Reducing ICU LOS will have variable, hospital-specific effects on ICU census and reimbursement, depending on local ICU bed pressures, case mix, and payer mix. Detailed economic studies of other interventions in emergency and critical care medicine are limited. Similar to our hospital case, intensive insulin therapy recently was associated with substantial hospital cost savings (42) , while drotrecogin alpha (activated) is associated with an increased hospital cost, al-though potentially favorable cost-effectiveness ratio (14) . It is difficult to compare our estimates to those for other systems-based approaches to acute illness, such as stroke centers (43) or trauma centers (44) , because these evaluations were conducted after the centers already had been established. Recent studies of trauma center effectiveness did not include economic evaluations (45) . Dr. Lieu and colleagues (46) conducted a decision analysis of primary angioplasty for myocardial infarction and found favorable cost-effective ratios for hospitals with existing cardiac catheterization laboratories, but relatively cost-ineffective ratios if redundant laboratories had to be built. Our analysis only applies to hospitals with a fully staffed ED and ICU, and EGDT may be less cost-effective in other settings.
Limitations. First, precisely estimating ED severe sepsis/septic shock epidemiology and an "average" ED is difficult.
We chose conservative estimates based on available data and our results were fairly insensitive to patient volume and staffing needs. However, our model does not adjust for potential volume-outcome relationships. Institutions that perform few ED resuscitations may deliver EGDT with lesser effectiveness. Conversely, such institutions' sepsis care and outcomes may improve the most from EGDT training and implementation. Second, EGDT is only one component of sepsis care, and was studied before publication of other important trials (47) . Sepsis care is increasingly "bundled," and EGDT's absolute mortality reduction, upon which our estimates were particularly sensitive, may be less today. Third, our models only apply to septic ED patients. Extension of EGDT to non-ED patients is beyond this paper's scope. Fourth, our analysis relied on multiple assumptions. While this affects the precision of our point estimates, sensitivity analysis supports our primary findings.
CONCLUSIONS
EGDT has important start-up costs, and modest delivery costs, but assuming LOS and mortality are reduced, EGDT can be cost-saving to the hospital and associated with favorable lifetime costeffectiveness projections. Figure 4 . Two-way sensitivity analysis (hospital case)-early goal-directed therapy implementation costs vs. hospital mortality reduction. Analysis was conducted within the emergency departmentbased implementation strategy. New programs always incur immediate extra costs, with uncertain effectiveness and only theoretical cost savings. We, therefore, ignored all potential future cost savings attributable to early goal-directed therapy (e.g., reduction in intensive care unit length of stay, mechanical ventilation) but modeled for all implementation costs ($1,141 per treated patient, for an average 29,100 patients per year emergency department, seeing 91 severe sepsis patients per year). We varied implementation costs from 50% to 200%, while simultaneously varying early goal-directed therapy's effect on hospital mortality from 0% to 100%. The vast majority of simulations fall below $50,000 per additional hospital survivor. Appendix 2. Derivation of mean emergency department (ED) nurse/annual patient volume ratio, from the staffing patterns of a convenience sample of seven emergency departments in Detroit, Pennsylvania, California, and Virginia a 
